Skip to main content
PAOG logo

PAO Group, Inc. (PAOG) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0002 $0.00 (0.00%)
Vol: 3.0K| 52-wk range: $0.0001 – $0.0008

P/E 4.06 means the share price is 4.06 times one year of earnings per share.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

PAO Group, Inc. (PAOG) trades at $0.0002. PAO Group, Inc. is a healthcare company focused on alternative patient care treatments. It develops, sells, and distributes premium medical cannabis products for chronic and terminal patients. Sector: Healthcare.

Price as of · Last analyzed: Mar 18, 2026
PAO Group, Inc. is a healthcare company focused on alternative patient care treatments. It develops, sells, and distributes premium medical cannabis products for chronic and terminal patients.

Analyst Coverage for PAOG: PAOG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • DCGO · DocGo Inc. · 22 /100
  • BTMD · biote Corp. · 39 /100
  • CCEL · Cryo-Cell International, Inc. · 33 /100

See all scored stocks →

PAO Group, Inc. (PAOG) Healthcare & Pipeline Overview

CEOJames C. DiPrima
Employees7
HeadquartersSandusky, US
IPO Year2009

PAO Group, Inc. operates within the healthcare sector, focusing on alternative patient care and premium medical cannabis products. The company targets chronic and terminal patients, differentiating itself through specialized treatment approaches in the evolving medical cannabis market. PAOG is headquartered in Sandusky, Ohio.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for PAOG?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

PAO Group, Inc. presents a speculative investment opportunity within the evolving medical cannabis market. With a market capitalization of $0.00B and a P/E ratio of 4.06, the company's valuation reflects its current stage of development. A key value driver is the increasing acceptance and legalization of medical cannabis, which could expand PAO Group's market reach. Upcoming catalysts include potential regulatory changes and expansion of the company's product line. However, the company's negative beta of -49.83 indicates high volatility and sensitivity to market fluctuations. Potential risks include competition from established players and regulatory uncertainties surrounding the medical cannabis industry. Investors should carefully consider these factors before investing in PAOG.

Based on FMP financials and quantitative analysis

PAOG Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

PAO Group, Inc. focuses on alternative patient care treatments within the healthcare sector.

  • The company develops, sells, and distributes premium medical cannabis products for chronic and terminal patients.
  • PAOG's P/E ratio stands at 4.06, reflecting its earnings relative to its stock price.
  • The company's beta is -49.83, indicating high volatility compared to the overall market.
  • PAO Group, Inc. does not currently offer a dividend to its shareholders.

Who Are PAOG's Competitors?

PAOG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
DCGO DocGo Inc. $0.17 +1.98% $17.3M —
BTMD biote Corp. $0.81 -3.56% $26.3M 39 5-pillar
CCEL Cryo-Cell International, Inc. $4.15 0.00% $33.5M 33 5-pillar
AIRS AirSculpt Technologies, Inc. $0.59 -9.72% $43.7M 33 5-pillar
JYNT The Joint Corp. $6.19 -3.73% $84.7M 73 5-pillar
CYH Community Health Systems, Inc. $1.62 +0.62% $228M 52 5-pillar
AUNA Auna S.A. $3.66 -6.15% $271M 59 5-pillar
PIII P3 Health Partners Inc. $1.69 -9.14% $350M 31 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PAOG's Key Strengths?

Focus on premium medical cannabis products.

  • Specialized care for chronic and terminal patients.
  • Established distribution network.
  • Proprietary formulations and product development.

What Are PAOG's Weaknesses?

Limited market capitalization.

  • High volatility.
  • Dependence on regulatory changes.
  • Competition from established players.

What Are the Key Risks for PAOG?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • Competition from established players in the medical cannabis industry.
  • Regulatory uncertainties surrounding the medical cannabis industry.
  • Market volatility and sensitivity to market fluctuations.
  • Limited financial disclosure and low liquidity due to trading on the OTC Other tier.
  • Potential for price manipulation and higher risk of fraud or scams.

What Are PAOG's Competitive Advantages?

  • Focus on premium medical cannabis products.
  • Specialized care for chronic and terminal patients.
  • Established distribution network.
  • Proprietary formulations and product development.

What Does PAOG Do?

PAO Group, Inc., headquartered in Sandusky, Ohio, is a healthcare company dedicated to alternative patient care treatments. The company operates through its subsidiaries, focusing on the development, sale, and distribution of premium medical cannabis products. These products are specifically designed for the treatment of chronic and terminal patients, addressing a growing demand for alternative therapies within the healthcare sector. PAO Group's business model centers around providing specialized care and products within the medical cannabis market. The company's evolution reflects the increasing acceptance and legalization of medical cannabis in various regions. By focusing on premium products and specific patient needs, PAO Group aims to establish a strong presence in the alternative healthcare market. The company's geographic reach is currently centered around its distribution network for medical cannabis products. PAO Group faces competition from other companies in the medical cannabis and alternative healthcare sectors, but differentiates itself through its focus on premium products and targeted patient care.

What Products and Services Does PAOG Offer?

  • Develop premium medical cannabis products.
  • Sell and distribute medical cannabis products to chronic and terminal patients.
  • Focus on alternative patient care treatments.
  • Operate through subsidiaries to manage different aspects of the business.
  • Target the medical cannabis market.
  • Provide specialized care and products for specific patient needs.

How Does PAOG Make Money?

  • Develop and manufacture premium medical cannabis products.
  • Distribute products through a network of dispensaries and healthcare providers.
  • Generate revenue through the sale of medical cannabis products.
  • Focus on chronic and terminal patients as their primary customer base.

What Industry Does PAOG Operate In?

PAO Group, Inc. operates within the medical cannabis industry, a segment of the healthcare sector experiencing rapid growth and evolving regulatory landscapes. PAOG competes with other companies in the medical cannabis space, as well as traditional pharmaceutical companies offering alternative treatments. The industry is characterized by ongoing research and development, regulatory changes, and increasing consumer demand for alternative healthcare solutions.

Who Are PAOG's Key Customers?

  • Chronic patients seeking alternative treatments.
  • Terminal patients requiring specialized care.
  • Dispensaries and healthcare providers distributing medical cannabis products.
  • Individuals seeking premium medical cannabis products.
Model self-rating on this text: 79% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage
F-Score 2/9

Financial Health

PAO Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE 8%

Key Financial Metrics

Return on equity for PAO Group, Inc. stands at 8.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -25.8%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

PAO Group, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO James C. DiPrima. PAOG has traded publicly since 2009.

PAOG Latest News

No recent news available for PAOG.

PAOG Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PAOG.

Price Targets

Wall Street price target analysis for PAOG.

PAOG MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PAOG; grades run from A+ (80-100) to F (below 30).

Leadership: James C. DiPrima

CEO

James C. DiPrima serves as the CEO of PAO Group, Inc. His background includes experience in the healthcare and cannabis industries. He has been involved in the development and commercialization of medical cannabis products. DiPrima's leadership focuses on driving growth and innovation within the company. He is responsible for strategic decision-making and overseeing the company's operations. His expertise in the medical cannabis market is crucial for PAO Group's success.

Track Record: Under James C. DiPrima's leadership, PAO Group, Inc. has focused on expanding its product line and distribution network. He has overseen the development of new medical cannabis products and the establishment of strategic partnerships. His strategic decisions have aimed at positioning PAO Group as a key player in the alternative patient care market. Key milestones include expanding the company's reach and increasing revenue streams.

PAOG OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that PAO Group, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Trading on the OTC Other tier is generally considered more speculative and carries higher risks compared to trading on regulated exchanges like the NYSE or NASDAQ.

  • OTC Tier: OTC Other
Liquidity: Liquidity for stocks on the OTC Other tier, like PAOG, is typically very low. This can result in wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. Low trading volume can also lead to price volatility and potential difficulties in executing large orders. Investors should be aware of the limited liquidity and potential for price manipulation when trading PAOG.
OTC Risk Factors:
  • Limited financial disclosure.
  • Low liquidity and high bid-ask spreads.
  • Potential for price manipulation.
  • Higher risk of fraud or scams.
  • Limited regulatory oversight.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Research the company's management team and their track record.
  • Check for any regulatory actions or legal issues.
  • Monitor trading volume and price activity.
  • Consult with a financial advisor before investing.
Legitimacy Signals:
  • Company website and contact information.
  • Publicly available news and press releases.
  • Presence on OTC Markets Group website.
  • Management team with relevant experience.
  • Focus on a specific market niche (medical cannabis).

What Investors Ask About PAO Group, Inc. (PAOG) — Healthcare

What does PAO Group, Inc. do?

PAO Group, Inc. is a healthcare company focused on alternative patient care treatments, specifically the development, sale, and distribution of premium medical cannabis products.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available for PAOG. OTC stocks carry higher risk.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives